Clinical significance of P16INK4A and retinoblastoma proteins in nonsmall-cell lung carcinoma

被引:18
作者
Akin, H
Yilmazbayhan, D
Kiliçaslan, Z
Dilege, S
Dogan, Ö
Toker, A
Kalayci, G
机构
[1] Istanbul Univ, Sch Med, Dept Pathol, Istanbul, Turkey
[2] Istanbul Univ, Sch Med, Dept Pulm Med, Istanbul, Turkey
[3] Istanbul Univ, Sch Med, Dept Thorac & Cardiovasc Surg, Istanbul, Turkey
关键词
lung carcinoma; non-small-cell; pRb; p16;
D O I
10.1016/S0169-5002(02)00301-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study was performed to determine the frequency of expression loss of p 16 and pRb; their relations with each other, tumour histology, tumour stage, nodal status, and,survival in formalin fixed, paraffin embedded tumour tissues of patients with non-small-cell lung carcinoma (NSCLC). P16 and/or pRb expression loss is observed in 72 (75.8%) out of 95 patients, and 70 (73.7%) of them showed inverse correlation (P < 0.05). Thirty-six (37.9%) of the p16 positive cases usually showed weak or moderate immunohistochemical staining. Loss of p16 expression was found to be significantly greater in squamous cell carcinoma than in adenocarcinoma cases, whilst no relation was observed with other clinical parameters. Immunohistochemical reactivity for pRb was generally moderate or strong. PRb expression loss was observed in 15.8% of the cases, and no relation was found between pRb loss and age, sex, tumour histology, tumour stage, or nodal status. PRb negative squamous cell carcinoma cases had significantly shorter survival independent of nodal status. These results suggest that disruption of p16/pRb pathway is frequently involved in NSCLC, and pRb expression loss in cases with squamous cell carcinoma may predict clinical outcome. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:253 / 260
页数:8
相关论文
共 30 条
[1]   Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis [J].
Belinsky, SA ;
Nikula, KJ ;
Palmisano, WA ;
Michels, R ;
Saccomanno, G ;
Gabrielson, E ;
Baylin, SB ;
Herman, JG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :11891-11896
[2]  
Brambilla E, 1999, J PATHOL, V188, P351, DOI 10.1002/(SICI)1096-9896(199908)188:4<351::AID-PATH385>3.0.CO
[3]  
2-W
[4]   New therapeutic strategies for lung cancer - Biology and molecular biology come of age [J].
Bunn, PA ;
Soriano, A ;
Johnson, G ;
Heasley, L .
CHEST, 2000, 117 (04) :163S-168S
[5]   Loss of p16 and/or pRb protein expression in NSCLC - An immunohistochemical and prognostic study [J].
Chen, JT ;
Chen, YC ;
Chen, CY ;
Wang, YC .
LUNG CANCER, 2001, 31 (2-3) :163-170
[6]  
DosakaAkita H, 1997, CANCER-AM CANCER SOC, V79, P1329, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1329::AID-CNCR9>3.0.CO
[7]  
2-B
[8]   THE EFFECT OF SURGICAL-TREATMENT ON SURVIVAL FROM EARLY LUNG-CANCER - IMPLICATIONS FOR SCREENING [J].
FLEHINGER, BJ ;
KIMMEL, M ;
MELAMED, MR .
CHEST, 1992, 101 (04) :1013-1018
[9]   Molecular pathogenesis of lung cancer [J].
Fong, KM ;
Sekido, Y ;
Minna, JD .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 118 (06) :1136-1152
[10]  
GERADTS J, 1995, CANCER RES, V55, P6006